← FDA DRUG APPROVALS

FDA ANDA · ANDA211757

CYCLOPHOSPHAMIDE

Sponsor: XGEN PHARMS

APPLICATION
ANDA211757
TYPE
ANDA
ORIGINAL APPROVAL
2022-10-18
LATEST ACTION
2022-10-18
ROUTE
INTRAVENOUS, ORAL, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CYCLOPHOSPHAMIDEPrescription
CYCLOPHOSPHAMIDE 1GM/VIAL · INJECTABLE · INJECTION
CYCLOPHOSPHAMIDEPrescription
CYCLOPHOSPHAMIDE 2GM/VIAL · INJECTABLE · INJECTION
CYCLOPHOSPHAMIDEPrescription
CYCLOPHOSPHAMIDE 500MG/VIAL · INJECTABLE · INJECTION

Approval history

2022-10-18UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →